Biologics

SpinalCyte received a new Australian patent related to its fibroblast technology.

DiscGenics' injectable disc cell therapy, IDCT, passed the initial safety review of its first-in-human trial for moderate degenerative disc disease treatment.

JRF Ortho provides allograft joint repair solutions.

The FDA granted StemCyte permission to proceed with its phase 2 investigational new drug application for the Allogenic Human Leukocyte Antigen-Matched Umbilical Cord Blood Mononuclear Stem Cells (MC001).

Carmell Therapeutics, a developer of plasma-based bioactive materials to accelerate bone and soft tissue healing, welcomed Wendy DiCicco to its board of directors.

The Department of Defense granted a team of researchers at the University of Arizona in Tucson $2 million to study bone regrowth technology, according to The Brunswick News.

Michael B. Gerhardt, MD, is a sports medicine specialist and orthopedic surgeon at Cedars-Sinai Kerlan-Jobe Institute in Los Angeles and team physician for the LA Galaxy and U.S. Soccer Men's National Team.

Here are 10 must-read Q&As from 2018 on biologics.

Robert LaPrade, MD, is an orthopedic surgeon based in Colorado.

The FDA warned Genetech and its president Edwin Pinos for manufacturing stem cell products without FDA approval and deviating from current good manufacturing practice requirements, which may have led to microbial contamination.